Patents Assigned to Cortexyme, Inc.
-
Publication number: 20210355527Abstract: Methods for detecting microbial nucleic acids in a body fluid of a subject are provided. The methods include highly sensitive and specific procedures for detecting DNA derived from the bacteria such as Porphyromonas gingivalis, e.g., using PCR amplification and qPCR detection, in clinical and/or laboratory samples containing CSF or other biofluids.Type: ApplicationFiled: September 27, 2019Publication date: November 18, 2021Applicant: Cortexyme, Inc.Inventors: Debasish Raha, Leslie J. Holsinger, Stephen S. Dominy, Casey C. Lynch
-
Publication number: 20210340105Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: July 8, 2021Publication date: November 4, 2021Applicant: Cortexyme, Inc.Inventors: Andrei W. Konradi, Robert A. Galemmo, JR., Casey C. Lynch
-
Publication number: 20210017167Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: May 4, 2020Publication date: January 21, 2021Applicant: Cortexyme, Inc.Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20200148642Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: November 8, 2019Publication date: May 14, 2020Applicant: Cortexyme, Inc.Inventors: Andrei W. Konradi, Robert A. Galemmo, JR., Casey C. Lynch
-
Publication number: 20190322659Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: April 30, 2019Publication date: October 24, 2019Applicant: Cortexyme, Inc.Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20180346460Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 4, 2018Publication date: December 6, 2018Applicant: Cortexyme, Inc.Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20180334440Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: May 9, 2018Publication date: November 22, 2018Applicant: Cortexyme, Inc.Inventors: Andrei Konradi, Stephen S. Dominy, Casey C. Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20170349537Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: August 22, 2017Publication date: December 7, 2017Applicant: Cortexyme, Inc.Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20160096830Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: October 5, 2015Publication date: April 7, 2016Applicant: Cortexyme, Inc.Inventors: Andrei KONRADI, Stephen S. DOMINY, Casey CRAWFORD LYNCH, Craig COBURN, Joseph VACCA
